For research use only. Not for therapeutic Use.
Iloprost (ZK 36374; CAT: I004892) is a synthetic analog of prostacyclin (PGI2), a naturally occurring substance in the body that plays a role in regulating blood vessel dilation and preventing blood clot formation. Iloprost mimics the effects of prostacyclin and acts as a potent vasodilator, promoting the relaxation of smooth muscle cells in blood vessels and improving blood flow. It is used in the treatment of various vascular conditions, including pulmonary arterial hypertension (PAH) and peripheral vascular disease (PVD). By enhancing vasodilation and inhibiting platelet aggregation, iloprost helps to improve symptoms and prevent further complications associated with these conditions.
Catalog Number | I004892 |
CAS Number | 78919-13-8 |
Synonyms | (E)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,4R,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid |
Molecular Formula | C22H32O4 |
Purity | ≥95% |
Target | Prostanoid Receptors |
Solubility | 10 mM in DMSO |
Storage | Desiccate at -20C |
Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>Iloprost is an e<span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>poprostenol agonist. </span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>CiVi Biopharma has received Orphan Drug status for Systemic scleroderma in USA in 2020.</span></span></span></span> |
IUPAC Name | (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid |
InChI | InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 |
InChIKey | HIFJCPQKFCZDDL-ACWOEMLNSA-N |
SMILES | O[C@@H]1C[C@H](C/2)[C@H](CC2=CCCCC(O)=O)[C@H]1/C=C/[C@@H](O)C(C)CC#CC |
Reference | <br /> |